Nuclear medicine vendor SMV has revamped its executive lineup,a move that has resulted in the departure of Colin McNaught, chairmanand CEO of the vendor's SMV America unit in Twinsburg OH, andAndre Debionne, chairman and CEO of the holding company for
Nuclear medicine vendor SMV has revamped its executive lineup,a move that has resulted in the departure of Colin McNaught, chairmanand CEO of the vendor's SMV America unit in Twinsburg OH, andAndre Debionne, chairman and CEO of the holding company for SMVAmerica and SMV International.
SMV spokesperson Robert Ripley said that Debionne's positionwas a transitional one designed to help smooth the integrationof SMV's predecessors, Sopha and Summit Nuclear, while McNaughtdeparted for personal reasons. McNaught previously was head ofSopha's U.S. unit.
Neither McNaught nor Debionne will be replaced, according toRipley. SMV International chief executive Jean Plazenet will assumethe responsibilities of both executives. Summit veteran RandallSommerdyke remains president of SMV America, Ripley said.
New Analysis Forecasts Substantial Cost Savings with the Use of Photon Counting CT for CCTA
March 8th 2025The use of ultra-high-resolution photon-counting CT in the evaluation of stable chest pain may significantly reduce follow-up tests and invasive coronary angiography (ICA) procedures, possibly resulting in millions in health-care cost savings, according to a cost-effectiveness analysis presented recently at the European Congress of Radiology.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.